SGLT2 Inhibitors tied to Superior Cardiorenal and Hepatic Outcomes in Diabetes patients With Cirrhosis: JAMA
A recent study published in the Journal of the American Medical Association revealed that the use of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) was associated with markedly lower risks of adverse…